About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Health Care and Law
Dr. Field discusses the benefits and drawbacks of disclosing clinical trial results to the public.
Robert I. Field, JD, MPH, PhD
The authors present an illustration of an innovative Hospital Quality Incentive Payment System for improved patient care.
Mark Baumel, MD, MS, Jeff Danilo, Linda Hart, Steve Brown, MD, Timothy Zeddies, PhD, Kathleen Clark, and Joseph C. Gallo, Jr.
Dr. Goldenberg reviews the role of the FDA, safety issues regarding new medical devices, and some of the possible reasons for their failure and recall.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
Dr. Yates discusses the use of two agents, pioglitazone and rosiglitazone, in the treatment of patients with type-2 diabetes after the removal of troglitazone from the market.
Scott W. Yates, MD, MBA
David Nash, MD, MBA, details some of the challenges involved in developing the contract language of clinical trials.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, discusses ways to prevent errors involving liquid medications.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses a large-scale effort to accelerate the arrival of electronic health records for patients in the U.S.
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
The authors review risperidone (Risperdal Consta™), the first long-acting atypical antipsychotic agent.
Suzanne Thompson, PharmD, and Jose A. Rey, PharmD